



FOR IMMEDIATE RELEASE

Oraya Therapeutics to Present at the Ophthalmology Innovations Summit and the American Academy of Ophthalmology Annual Meeting

NEWARK, CA. October 20, 2009— Oraya Therapeutics of Newark, California, today announces its participation in the Ophthalmology Innovation Summit (OIS), to be held at the Palace Hotel in San Francisco on October 22, 2009, preceding the annual meeting of the American Academy of Ophthalmology (AAO). The Summit will bring together leaders in the development of ophthalmic products, drugs, and devices.

Oraya Therapeutics will present a summary of its innovative office-based stereotactic radiotherapy technology, currently undergoing clinical evaluation for the treatment of wet age-related macular degeneration (AMD). The OIS presentation will be followed during AAO's Retina 2009 Subspecialty Day on October 23rd by a synopsis of the clinical data from CLH001, Oraya's human safety and feasibility study that has been underway since August 2008.

AMD is the leading cause of blindness in the elderly. The disease is believed to arise from inflammatory processes which lead to neovascularization, leakage, scar formation, and/or atrophy of the retina. Oraya's IRay™ device is designed to deliver a highly localized dose of X-ray radiation to the macula using a novel and proprietary positioning system, targeting algorithm, and component for eye stabilization. Radiation is long known to inhibit multiple inflammatory pathways, as well as to have a direct deterring effect on neovascular capillaries and scar formation, and thus holds considerable promise for the treatment of AMD.

About Oraya Therapeutics:

The IRay is limited by U. S. Federal Law to investigational use.

Oraya Therapeutics, Inc. is a privately-held company developing innovative and non-invasive therapies for diseases of the eye. The company was founded in 2007. Its investors include Essex Woodlands Health Ventures, Domain Associates, Scale Venture Partners, and Synergy Life Science Partners. The company's first commercial application, the IRay system, is currently undergoing clinical trials for the treatment of wet age-related macular degeneration. More information about Oraya Therapeutics can be found at www.orayainc.com.

Media contact:

Kate Jennings
Maricich Brand Communications
949-223-6455
kate@maricich.com